Piper Sandler initiated coverage of Day One Biopharmaceuticals (DAWN) with an Overweight rating and $25 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Promising Growth and Stability Drive Buy Rating for Day One Biopharmaceuticals
- Day One Biopharma’s Earnings Call Highlights Growth and Strategy
- Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals
- Buy Rating for Day One Biopharmaceuticals Amid Promising Future Catalysts Despite Current Challenges
- Day One Biopharmaceuticals price target lowered to $17 from $20 at BofA